Yamamoto group demonstrated that local injection of LAP inhibits dermal sclerosis in bleomycin-induced murine scleroderma [50], Sandra Boswell team discovered a new peptide GPC81-95 can induce CD4+ T cells surface expression of LAP increase immune suppression of CD4+LAP+ Tregs [51], suggesting that increasing the numbers and enhancing the function of CD4+LAP+ Tregs may be a feasible therapeutic approach for treatment of chronic inflammatory diseases like ACS. The gene discussed is CD4; the disease is scleroderma.